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Abstract
MYC-mediated pathogenesis in lung cancer continues to attract
interest for new therapeutic strategies. In this study, we describe a
transgenic mouse model of KRAS-driven lung adenocarcinoma
that affords reversible activation of MYC, used here as a tool for
lipidomic proﬁling of MYC-dependent lung tumors formed in
this model. Advanced mass spectrometric imaging and surface
analysis techniques were used to characterize the spatial and
temporal changes in lipid composition in lung tissue. We found
that normal lung tissue was characterized predominantly by
saturated phosphatidylcholines and phosphatidylglycerols,
which are major lipid components of pulmonary surfactant. In
contrast, tumor tissues displayed an increase in phosphatidyli-
nositols and arachidonate-containing phospholipids that can
serve as signaling precursors. DeactivatingMYC resulted in a rapid
and dramatic decrease in arachidonic acid and its eicosanoid
metabolites. In tumors with high levels of MYC, we found an
increase in cytosolic phospholipase A2 (cPLA2) activity with a
preferential release of membrane-bound arachidonic acid, stim-
ulating the lipoxygenase (LOX) andCOXpathways also ampliﬁed
byMYCat the level of gene expression.DeactivatingMYC lowered
cPLA2 activity along with COX2 and 5-LOX mRNA levels. Nota-
bly, inhibiting the COX/5-LOX pathways in vivo reduced tumor
burden in a manner associated with reduced cell proliferation.
Taken together, our results show how MYC drives the produc-
tion of speciﬁc eicosanoids critical for lung cancer cell survival
and proliferation, with possible implications for the use of
COX and LOX pathway inhibitors for lung cancer therapy.
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Introduction
Non–small cell lung cancer is a leading cause of cancer-
related death. The single name encompasses several genetically
distinct pathologies, and increasingly efforts to identify thera-
pies for this disease have attempted to target speciﬁc mutations.
In adenocarcinoma, more than a third of tumors have an
activating mutation in KRAS, and MYC has been shown to be
frequently overexpressed (1). Although the oncogenic activa-
tion of MYC results in uncontrolled cell proliferation (2), MYC
inhibition leads to tumor regression and redifferentiation of
cells (3, 4). As such MYC is an attractive candidate for cancer
drug therapies; however, all its functions and interactions are
not fully understood.
Cancer cell proliferation is typically accompanied by meta-
bolic reprogramming, with increased glucose uptake and aer-
obic glycolysis, as part of the Warburg effect (5). In addition,
cancer cells synthesize lipids through de novo lipogenesis (5).
These lipids play a structural role in new cell membranes and
are likely to be further involved in signaling events important
for cancer development (5, 6). Although the precise role of
aberrant lipid biosynthesis is unknown, several studies have
shown that the lipid proﬁle has been linked to survival, ER
status, and tumor grade in human breast cancer (7, 8). The lipid
composition of tumors is also affected by dynamic processes,
having been observed to vary with cell proliferation, apoptosis,
and necrosis (9). Furthermore, a recent study has revealed
distinct lipid signatures in MYC- or RAS-induced lymphoma,
suggesting that the observable lipid proﬁle can be related to
speciﬁc oncogene expression (10). In addition to genotype
speciﬁcity, evidence suggests that metabolic proﬁles are highly
tissue speciﬁc (11).
Here, we use a novel transgenic mouse model of KRASG12D-
driven lung adenocarcinoma with reversible activation of
MYC, to study changes to the lung lipid proﬁle following
tumorigenesis with high MYC activity, and subsequent deac-
tivation of MYC over time. We characterized the changes in
lipid composition and abundance using matrix-assisted laser
desorption ionization-mass spectrometry imaging (MALDI-
MSI) and liquid extraction surface analysis-mass spectrometry
(LESA-MS). MALDI-MSI is ideally placed for in situ molecular
mapping since lipids are directly ablated and ionized from
tissue by a moving laser pulse, retaining critical spatial infor-
mation (12–15). In LESA-MS lipids are extracted directly from
the surface of tissue with solvent, providing an orthogonal
approach to the direct analysis of lipids from tissues (16–18).
This allowed us to follow lipidome changes and to map these
effects across the tissue.
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Overall, we established the lipid signatures for normal and
tumor lung tissue in mice with increased MYC activity and
endogenous levels of oncogenic KRAS. We found that normal
tissue was predominantly characterized by pulmonary surfac-
tant lipids, whereas tumor tissue had increased signaling
precursor phospholipids, such as the phosphatidylinositols
and arachidonate-containing phospholipids. We observed an
increase in free arachidonic acid, which is released from mem-
brane phospholipids by cytosolic phospholipase A2 (cPLA2),
in tumors with high MYC activity and linked this to increased
cPLA2 activity. Moreover, we report evidence at the metabolite
and gene-expression level, linking MYC to increased synthe-
sis of arachidonic acid-derived eicosanoids via the lipoxy-
genase (LOX) and COX pathways. Following MYC deactiva-
tion, speciﬁc metabolites and mRNAs associated with these
pathways, and cPLA2 activity, decreased with time. By inhibit-
ing the COX and 5-LOX pathways in high MYC mice, a re-
duction in tumor proliferation and increase in apoptosis was
observed, highlighting these pathways as potential drug targets
for lung cancer.
Materials and Methods
Tumor models
Lung tumors were generated by intranasal delivery of adeno-
Cre (7  106) virus particles to either Krastm4Tyj(LSL-KrasG12D)
mice, which express oncogenic KrasG12D upon Cre-mediated
deletion, or LSL-KrasG12D; R26LSL-CAG-c-MycER/LSL-CAG-c-MycER
(R26LSL-CMER) mice, which in addition to oncogenic KRAS
express a high level of deregulated c-MYCERT2 [driven by a
CAGGs (chicken b-actin/CMV) enhancer] from the Rosa26
locus. The Rosa26 model of c-MYCERT2 is regulated at two
levels; expression of cre-recombinase is necessary to remove
the stop element and addition of tamoxifen to the diet is
necessary to activate the c-MYCERT2 protein, providing a means
to activate or deactivate MYC (19). Detailed characterization
of this novel mouse model will be described elsewhere (man-
uscript in preparation).
Ten adeno-Cre–injected LSL-KrasG12D;R26LSL-CMERmice were
fed a tamoxifen-containing diet for 4 weeks. Tamoxifen was
removed from the diet for 24 hours (n¼ 3) or 72 hours (n¼ 3),
to deactivate MYC (referred to as "MYC inactive") before
culling. The remaining mice (n ¼ 4, referred to as "MYC
activated") were maintained on the tamoxifen-containing diet
continuously. As a further control and to ensure the overall
lipid content was not altered by the addition/removal of tam-
oxifen, LSL-KrasG12D mice, where MYC expression was not
controlled (referred to as "KRAS only"), were maintained
either on a tamoxifen-containing (n ¼ 2) or normal diet
(n ¼ 2). Lung samples were collected, snap-frozen with liquid
nitrogen and stored at 80C. Samples were embedded in
Tissue-Tek OCT and 12-mm frozen sections on glass micro-
scope slides were prepared using a cryostat. Adjacent sections
were stained with hematoxylin and eosin (H&E). All animal
procedures were approved by the UK Home Ofﬁce and the
University of Cambridge.
MALDI imaging MS
Matrix solutions of 10 mg/mL [2,5-dihydroxybenzoic acid
(DHB; Sigma-Aldrich) or 2, 4, 6-trihydroxyacetophenone mono-
hydrate (THAP; Sigma-Aldrich)] were administered to the tissue
surface using a nebulized sprayer (Suncollect MALDI spotter, KR
Analytical Ltd.). Imaging experiments were carried out using a
MALDI LTQ Orbitrap XL (Thermo Fisher Scientiﬁc) at 50-mm
step increments across the tissue. The chemical composition of
the lipid head group determines whether it has a greater pro-
pensity to form positive or negative ions. To detect as many
different lipid species as possible, spectra were acquired in
positive (DHB) and negative (THAP) ion mode, from 250 to
1,000 m/z at 60,000 resolution. Mass accuracy in positive and
negative ion mode was approximately 1 and 10 ppm, respec-
tively. Lipid identity was performed by accurate mass using the
Lipid Maps database (accessed December 2015; ref. 20). The
predominant fatty acid composition of lipids was conﬁrmed
where possible by collision-induced dissociation (CID). Naþ and
Kþ lipid adducts commonly observed in positive ion mode using
MALDI have a low yield of stable charged fragments. Therefore,
to improve fragmentation efﬁciency in positive ion mode, the
formation of lithium adducts more prone to fragmentation (21)
was induced by a 5-second washing step in lithium nitrate
(100 mmol/L) before deposition of matrix, and the correspond-
ing lithiated ions subjected to fragmentation by CID.
LESA-MS
Lipids were extracted using LESA at multiple user-deﬁned
points (1 mm2) across the tissue surface by dispensing 0.8 mL
1:2:4 chloroform: methanol: isopropanol with 10 mmol/L
ammonium formate, and incubating for 2.5 seconds. Analytes
extracted from the surfacewere infusedusing a TriversaNanomate
(Advion BioSciences), with capillary voltage 1.4 kV, 0.3 gas ﬂow
for 1 minute into an LTQ Orbitrap Elite (Thermo Fisher Scien-
tiﬁc). Spectra were acquired in positive and negative mode, from
200 to 1,000 m/z at 60,000 resolution.
Data processing
Data from MALDI-MSI were converted to imzML format for
processing (22). Using an in-house R script ions were retained
above a threshold intensity and them/z ratio of ions detectedwere
summed across integral regions of 10 ppm to allow for alterations
in m/z mass accuracy across the experiment ("binning"). Only
features detected above a threshold proportion of pixels were
retained. Ion intensities were normalized to the total ion count,
before creating two-dimensional ion images. Clustering of pixels
was performed using k-means clustering (23), to deﬁne tumor
and normal tissue regions, and to establish the average spectra in
each region from the cluster centers (Supplementary Fig. S1).
Data from LESA-MS were converted to mzML format for
subsequent data processing, and features were picked using an
in-house R script. Orthogonal projection to latent structures
discriminant analysis (OPLS-DA) models (24) were constructed
using SIMCA 14 (Umetrics), following normalization to the
total ion count, and Pareto scaling (25). For univariate statistics,
P values were determined using Student t tests (a ¼ 0.05) and
are adjusted for multiple testing using the Benjamini–Hochberg
procedure.
Eicosanoid assay
Ten microliters of butylated hydroxytoluene (0.2 mg/mL, Sig-
ma-Aldrich), 40 mL of an internal standard mix (containing
100 nmol/L each of 12-HETE-D8, PGE2-D4, and 8-iso-PGF2a-
D4, Cayman Chemical Company), and 1 mL of methanol were
added to approximately 100 mg of frozen tissue sample, which
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was homogenized using a TissueLyser (Qiagen Ltd.) for 10 min-
utes at 30 Hz. Samples were centrifuged (17,000  g, 5 minutes)
and the supernatants dried down under nitrogen and reconsti-
tuted in 40 mL 1:1 (v/v) methanol: water. Samples were analyzed
on a QTRAP 5500 (ABSciex UK Limited) coupled to an ACQUITY
Ultra Performance Liquid Chromatography (UPLC) system
(Waters Ltd.). Themobile phase gradient (0.5mL/min) is detailed
in Supplementary Table S1; mobile phase A was 0.1% acetic
acid in water, mobile phase B was 0.1 % acetic acid in aceto-
nitrile: methanol 80:20. Sample was injected (10 mL) into a
Kinetex 2.6 mm XB-C18 100 Å column (100 2.1 mm, Phenom-
enex) at 30C. The electrospray source was operated in negative
ion mode (4.5 kV and 650C). Mass transitions of 51 analytes
and 3 isotopically labeled standards (Supplementary Table S2)
were acquired in scheduled MRM mode. Peaks were integrated
by the Quantitation Wizard within Analyst version 1.6 and
normalized against wet tissue weight and to the intensity of the
internal standards.
IHC
Staining was performed on 4-mm parafﬁn-embedded sec-
tions. Sections were deparafﬁnized, treated with citrate buffer
for epitope retrieval, and endogenous peroxidases blocked in
3% H2O2. Immunohistochemical staining was performed using
the Rabbit VECTASTAIN ELITE ABC horseradish peroxidase kit
(Vector Laboratories) following the manufacturer's protocol.
Primary antibodies were anti-Ki67 (Thermo Scientiﬁc; clone:
SP6; 1:200), anti-caspase-3 antibody (Cell Signaling Technolo-
gy; clone; 5A1E 1:2,000), anti–c-MYC antibody (Y69; Abcam;
ab32072; 1:1,000), anti-phospholipase A2 (Abcam; ab58375:
1:1,000) and anti-phospholipase A2 (phospho Ser505; Abcam;
ab53105; 1:200). Staining was imaged on a Zeiss Axio Imager
using the Zeiss AxioVision 4.8 software. Quantiﬁcation was
performed by counting number of positive cells per tumor area
for 5 images; the mean of 5 raw counts was calculated and
represents one data point per graph.
Phospholipase A2 activity assay
Enzymatic activity was assessed using the Cytosolic Phospho-
lipase A2 Assay Kit (Abcam; ab133909) following the manufac-
turer's instructions. Calcium-independent PLA2 activity was
inhibited by the addition of bromoenol lactone, and secretory
PLA2 isoforms removed using a membrane ﬁlter with the molec-
ular weight cut-off value 30 kDa. Activity was normalized to total
protein content.
Transcript quantiﬁcation by qPCR
Total RNA was extracted and puriﬁed from homogenized
frozen lung tissue (20 mg) using the RNeasy Mini Kit (Qiagen),
following the manufacturer's protocol. Puriﬁed RNA concentra-
tion was quantiﬁed at 260 nm using a NanoDrop 100 (Thermo
Fisher Scientiﬁc). Genomic DNA contamination was eliminated
and complimentary DNA produced using the RT2 First Strand Kit
(Qiagen). Relative abundance of transcripts of interest was
assessed by quantitative-PCR in RT2 SYBR Green Mastermix
(Qiagen) with a StepOnePlus detection system (Applied Bios-
ciences). RT2 primer assays for mouse Rn18s (endogenous con-
trol), Pla2g4a (cPla2), Ptgs2 (Cox2), Alox5, Alox15, Alox12, Tnf-a,
Il1b were obtained from Qiagen. Expression levels were normal-
ized to endogenous controls using the DDCt method and fold
changes reported were relative to the "KRAS-only" group (tamox-
ifen diet). Additional mouse lung samples were prepared such
that 4 to 6 replicates were used per group. Statistical signiﬁcance
was determined using one-way ANOVA (a ¼ 0.05) and adjusted
for multiple comparisons using the Holm–Sidak method.
In vivo inhibitor study
Eight adeno-Cre infected LSL-KrasG12D;R26LSL-CMER mice were
fed a tamoxifen-containing diet as described above. Two weeks
following the administration of tamoxifen diet, mice were treated
with licofelone (n¼4) or vehicle (n¼4) once daily for 4 days, and
culled 2 hours following the ﬁnal treatment. Licofelone (Calbio-
chem; #435801), was freshly suspended in sunﬂower oil at a
concentration of 20 mg/mL and given by oral gavage at a dose of
100 mg/kg.
Results
Tumors have distinct lipid signatures to normal tissue
First, we sought to characterize the lipid signature in KRAS-
driven lung tumors with increased MYC activity, and compare
this to the lipid proﬁle of adjacent normal tissue using MALDI-
MSI. To distinguish between normal and tumor tissue, pixels of
each image were clustered according to their spectral similarity
(Fig. 1A). This was validated by comparing with histologic
features in adjacent H&E-stained sections (Fig. 1), and the
average spectra of the tumor and normal tissue in both positive
and negative mode compared (Fig. 1B and C). Using their
accurate masses, and database searching (Supplementary
Table S3) the majority of ions observed in positive ion mode
were found to be sodiated (Naþ) and potassiated (Kþ) adducts
of phosphatidylcholines (PC) and their corresponding frag-
ment ions (partial loss of head group, D m/z 59.074), whereas
in negative ion mode spectra were predominantly characteri-
zed by deprotonated phosphatidylinisotols (PI), phospha-
tidylglycerols (PG), and free fatty acids (FFA). Characteristic
product ion spectra were used to conﬁrm lipid class and fatty
acid composition (Supplementary Table S4).
Notable differences were observed in the lipid proﬁles of
normal and tumor tissue (Figs. 1B and 2A). We found that the
lipid proﬁle of normal tissue was predominantly characterized
by PC(32:0) (m/z 756.550 [MþNa]þ and m/z 772.526 [MþK]þ;
composed of fatty acids 16:0/16:0 according to fragmentation
data; Supplementary Table S4) and PC(32:1) (m/z 754.535
[MþNa]þ and m/z 770.510 [MþK]þ; 16:0/16:1). In contrast,
tumor tissue contained a wider distribution of lipids, including
PC(34:1) (m/z 782.568 [MþNa]þ and m/z 798.542 [MþK]þ;
16:0/18:1) and PC(34:2) (m/z 780.552 [MþNa]þ and m/z
796.526 [MþK]þ; 16:0/18:2). In particular, PC(36:4) (m/z
804.552 [MþNa]þ and m/z 820.526 [MþK]þ; 16:0/20:4) had
a signiﬁcantly increased relative abundance in tumors compared
with normal tissue. Ion images for the two most distinguishing
ions, PC(32:0) [MþNa]þ for normal tissue and PC(36:4)
[MþK]þ for tumors, were created highlighting their regiospeci-
ﬁcity (Fig. 2B and C). Interestingly, differences were observed
for the distribution of salt adducts, with a higher proportion
of sodiated lipids present in normal tissue, and potassiated
lipids in tumor regions (Fig. 2D–F).
Similarly, the lipid proﬁles in negative ion mode were
examined (Fig. 1C; Supplementary Fig. S2). The most abundant
species in both tissue types was PI(38:4) (m/z 885.539 [M-H];
18:0/20:4; Supplementary Table S3), whereas the second most
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abundant species was PG(34:1) (m/z 747.509 [M-H]; 16:0/
18:1) in normal tissue and PI(36:4) (m/z 857.508 [M-H];
16:0/20:4) in tumor tissue (Fig. 1C; Supplementary Table
S3). Overall tumor tissue had an increased relative abundance
of PIs, whereas normal tissue had an increased relative PG
content (Supplementary Fig. S2B and S2C). Free fatty acids
revealed a relative increase in palmitic acid, FFA(16:0) [M-H],
in normal tissue and in arachidonic acid, FFA(20:4) [M-H],
in tumor tissue, in line with observations for the PCs (Supple-
mentary Fig. S2A).
We complemented our results from MALDI-MSI with LESA-
MS, which was carried out on different sections of the same
samples (Supplementary Fig. S3). Lipids were extracted at
multiple sites in both tumor and adjacent normal tissue and
directly infused to the MS. Lipids identiﬁed in positive and
negative ion mode were combined, and an OPLS-DA model
built to identify which lipid species were important for classi-
fying samples as either normal or tumor (Supplementary Fig.
S3). Analysis supported the results from MALDI-MSI, and
suggest that PC(32:0) [MþH]þ was the most distinguishing
ion for normal tissue, whereas free arachidonic acid and related
lipids, including PC(36:4) [MþH]þ, were the most important
lipid species differentiating tumor tissue.
Imaging MS distinguishes tumor models with different MYC
activities
Having established the major differences in lipid proﬁles
between normal and tumor tissue, we sought to identify the
lipid proﬁle differences attributable to high MYC activity.
Removing tamoxifen from the diet results in rapid MYCER-
fusion protein deactivation over the course of 24 hours (26). As
a consequence of MYC deactivation, reduced tumor prolifer-
ation and apoptosis were observed (Supplementary Fig. S4A
and S4B). Using MALDI-MSI, we therefore compared lung
sections from LSL-KrasG12D;R26LSL-CMER mice with high MYC
activity ("MYC activated") and those after 72 hours MYC
deactivation ("MYC inactive"). As a control to ensure the
overall lipid content was not altered by the addition of tamox-
ifen to the diet, we also examined lung tumors from LSL-
KrasG12D mice on a tamoxifen-containing diet, where MYC
expression was low and unmodiﬁed ("KRAS only"; Supple-
mentary Fig. S4C).
We examined the spatial distributions for PC(36:4) [MþK]þ
and PC(32:0) [MþNa]þ—the most distinguishing lipid species
for tumor and normal tissue, respectively (Fig. 3A–C). A strik-
ing difference in the relative abundance of PC(36:4) was noted
between the three tumor models (Fig. 3D). PC(36:4) accounts
for a large proportion of the overall signal intensity in "MYC-
activated" tumors (Fig. 3B). On the other hand, after deacti-
vation of MYC the relative abundance of PC(36:4) in tumors
was dramatically reduced (Fig. 3C). "KRAS-only" tumors had
lower relative PC(36:4) content than "MYC activated," but
higher than "MYC inactive," highlighting the effect that speciﬁc
oncogenes or combinations thereof can have on the lipid
proﬁle. In-line with previous observations (27), PC(36:4) was
also observed to localize prominently in the airway linings—
this was more notable in the "MYC inactive" and "KRAS-only"
samples.
Figure 1.
Lipid signatures in normal and high MYC tumor tissue in lung. A, using MALDI-MSI and clustering, normal (green) and tumor (red) lung tissue were
differentiated by their mass spectra. The average spectra in positive (B) and negative (C) ion modes for normal and tumor tissue clusters are shown. The inset
shows an adjacent H&E-stained section of lung. Tumors are depicted by densely packed cells and stained dark pink, whereas normal tissue is thin and
ﬁlled with voids. A blood vessel can be observed in the top center of the section (orange).
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MS suggests a role for arachidonic acid in MYC-dependent
tumor models
We next focused on LESA-MS to further probe differences in
the lipid proﬁle for the three tumor types ("MYC activated,"
"MYC inactive," and "KRAS only"). Mass spectra were obtained
in positive and negative ion modes. In positive ion mode, the
most prominent lipids were protonated PCs (Fig. 4A). The
lipid proﬁles for "MYC inactive" and "KRAS-only" tumor sam-
ples looked broadly similar, with a high relative content of PC
(32:0) (m/z 734.569; [MþH]þ) and PC(32:1) (m/z 732.555;
[MþH]þ). However, the lipid proﬁle for "MYC-activated"
tumor samples was strikingly different, with a notable relative
increase in longer chain PCs, including PC(36:4) (m/z 782.569;
[MþH]þ; Fig. 4A). In negative ion mode, a wider distribution
of lipids was observed, including formate adducts of PCs,
and deprotonated PIs, PGs, phosphatidylethanolamines (PE),
plasmalogens, and free fatty acids (Fig. 4B). Of particular,
note was a marked increase in the relative abundance of
free arachidonic acid (m/z 303.234; [M-H]) in "MYC activat-
ed" tumors compared with "MYC inactive" and "KRAS-only"
tumors (Fig. 4B).
Identiﬁed features in positive and negative mode were
combined and used to construct an OPLS-DA (Fig. 4C)
model. There was clear grouping of the three tumor classes
(R2 ¼ 0.98, Q2 ¼ 0.91). Examination of the corresponding
loadings plots (Fig. 4D) revealed that the most important
lipid species for distinguishing "MYC activated" tumors was
arachidonic acid, which was increased relative to the other
two groups.
To further establish the changes in arachidonate, we exam-
ined the relative abundance of free arachidonic acid and related
lipids, including its precursor linoleic acid [FFA(18:2)] and
arachidonate-containing lipids PC(36:4) (16:0/20:4) and PC
(38:4) (18:0/20:4). In all cases, a decrease over time was
observed following deactivation of MYC: this was particularly
notable for arachidonic acid itself. This can be attributed to the
lower MYC level and not to diet, because lipid abundances in
"KRAS-only" controls on normal and tamoxifen-containing
diets were not signiﬁcantly different (Fig. 4E).
Increased eicosanoids implicated in tumors with high MYC
activity
Arachidonic acid is the major precursor for eicosanoids,
important signaling molecules responsible for regulation of
the inﬂammatory response, and implicated in facilitating can-
cer progression (28, 29). Because of their low abundance,
eicosanoids and related lipid mediators are not easily detected
by imaging techniques, and were therefore extracted from lung
tissue and analyzed using liquid chromatography-tandemmass
spectrometry (LC-MS/MS). On the basis of chromatographic
retention times and characteristic fragmentation pathways
(Supplementary Fig. S5; Supplementary Table S2), we detected
44 different eicosanoids and lipid mediators, 28 of which were
derived from arachidonic acid. Identiﬁed species included
10 prostaglandins, 2 leukotrienes, 6 hydroxyeicosatetranoic
acids (HETE), 4 epoxyeicosatrienoic acids (EET), 4 dihydrox-
yeicosatrienoic acids (DHETs), 3 hydroxyeicosapentaenoic
acids (HEPE), 2 dihydroxyoctadecanoic acids (DiHOME), and
Figure 2.
Characterizing the lipidome in KRAS-driven lung tumors, with high MYC activity. Relative abundances of major phosphatidylcholines (PC) in tumor
compared with normal lung tissue determined by MALDI-MSI. A, the intensities for multiple adducts were summed for each lipid species. B and C, two-
dimensional ion images for PC(32:0) ([MþNaþ]; m/z 756.550; B) and PC(36:4) ([MþKþ]; m/z 829.526; C) show a predominantly normal or tumor tissue
distribution, respectively. D, relative proportion of sodiated or potassiated PC adducts in tumor and normal tissue. E and F, MALDI-MSI images for sodiated
(m/z 754.535; E) and potassiated (m/z 770.510; F) PC(32:1) show different spatial distributions. Data are mean (n ¼ 3)  SEM ( , P < 0.05).
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2 hydroxyoctadecadienoic acids (HODE). Interestingly, many
of the identiﬁed species were found to be increased in "MYC-
activated" samples, and the top 10 most increased eicosanoids
were all arachidonic acid-derived (Supplementary Table S5).
Using multivariate statistics (Supplementary Fig. S6A and S6B),
we determined that the most important eicosanoids for distin-
guishing "MYC-activated" samples from the other groups were
the HETEs, which were present at higher concentrations in
"MYC-activated" samples (Fig. 4F). In addition to the HETEs,
levels of prostaglandins (including PGE2 and PGF2a), throm-
boxanes (TxB2) and leukotrienes (LTB4), amongst others, were
increased in "MYC-activated" lung tissue (Fig. 4F; Supplemen-
tary Table S5).
MYC linked to cPLA2 activity and COX/LOX expression
The observed increase in arachidonic acid-derived eicosa-
noids in "MYC-activated" tumors could arise from enhanced
substrate availability through increased cPLA2 expression or
activity, from increased expression of LOX/COX, or a com-
bination of the above. To test this, we performed immunos-
taining on LSL-KrasG12D;R26LSL-CMERtumors before and after
MYC deactivation. We stained speciﬁcally for the active phos-
phorylated form (Fig. 5A), ﬁnding a higher number of pos-
itively-stained cells for the "MYC-activated" tumors, with a
signiﬁcant decrease over time following MYC deactivation
(Fig. 5A and B). We then veriﬁed cPLA2 activity using an
enzyme activity assay (Fig. 5C), which conﬁrmed the signif-
icantly higher phospholipase activity in "MYC-activated" tis-
sue. Interestingly, when examining the staining, we noticed
that in many instances positively-stained cells were visibly
undergoing cell division, suggesting a proliferative role for
cPLA2 (Fig. 5D).
Next, we examined the gene expression in lung tissue from
LSL-KrasG12D;R26LSL-CMERmice, before and after MYC deactiva-
tion. We quantiﬁed transcripts for cPLA2 (cPla2), COX-2 (Cox2),
5-LOX (Alox5), 12/15-LOX (Alox15), and platelet-type 12-LOX
(Alox12). As a reference group, we used lung tissue from LSL-
KrasG12D mice. No difference in cPla2mRNA levels was observed
between whole lung tissue containing "KRAS-only" and "MYC-
activated" tumors (Fig. 5E). However, upon MYC deactivation
there was a signiﬁcant increase in mRNA levels after 72 hours,
which may be a compensatory effect to the overall reduction in
cPLA2 activity. This suggests the changes observed in cPLA2
activity with MYC activation/deactivation are not governed at
the transcriptional level. In contrast, transcript levels for Cox2
and Alox5 were signiﬁcantly increased in "MYC activated" com-
pared with "KRAS-only" lung tissue (Fig. 5E). Following MYC
deactivation, these transcripts decreased with time, suggesting
their ampliﬁcation at the gene expression level is linked to MYC.
Finally, we examined the gene expression for proinﬂammatory
cytokines TNF-a and IL-1b, that may play a role in regulating
cPLA2 and eicosanoid synthesis (30–33). We found a modest
increase in Tnf-a with MYC activation, whereas Il-1b gene
expression was closely correlated to MYC activity (Fig. 5F).
In vivo inhibition of COX/5-LOX pathways reduces
proliferation in lung tumors
We have shown that COX-2 and 5-LOX transcripts and meta-
bolites are linked to MYC activity in KRAS-driven adenocarcino-
ma. To conﬁrm the importance and assess the feasibility of
Figure 3.
MS imaging differentiates between levels of MYC activity. A–C, MALDI-MSI was carried out on lung tissue containing tumors driven by oncogenic KRAS only
(A), with MYC activated (B), and with MYC deactivated for 72 hours (C). The spatial distributions of PC(36:4) [MþKþ] is shown in red (top) and
overlaid with that of PC(32:0) [MþNaþ] in green (middle). Brighter intensity of color indicates higher ion abundance. Adjacent sections stained with H&E
were used as a reference (bottom). D, the relative proportion of signal for PC(36:4) was compared for the three different tumors and found to be
substantially higher in MYC-activated tumors. Data are mean (n ¼ 2 or 3)  SEM.
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targeting these pathways for the treatment of such lung cancers,we
designed an in vivo inhibitor study using the novel LSL-KrasG12D;
R26LSL-CMER mouse model, with MYC activated. Mice were
infected with adeno-Cre and transferred to a tamoxifen-contain-
ing diet, as in the earlier experiments. Two weeks following the
addition of tamoxifen, mice were treated with either vehicle or
licofelone—a dual COX/5-LOX pathway inhibitor, which has
shown promising chemopreventive efﬁcacy in lung and colon
cancers (34, 35). Remarkably, after only four doses we found
substantially reduced tumor load when compared with vehicle-
treated controls (Fig. 6A). To investigate this further, we per-
formed staining for proliferation (Ki67; Fig. 6B and C) and
apoptosis (cleaved caspase-3, Fig. 6D). We found increased apo-
ptosis (although this did not reach signiﬁcance) and signiﬁcantly
decreased proliferation (Fig. 6C) in tumors. Using mass spec-
trometry, we conﬁrmed that the COX-2/5-LOX metabolites had
been reduced, as anticipated (Fig. 6E).
Discussion
Here, we have probed the lipid proﬁles of mouse lung tumors
with oncogenic KRAS and increased MYC activity, comparing
Figure 4.
Arachidonic acid-related lipids differentiate lung tumors with varying MYC activities. A and B, typical LESA mass spectra for lung tumors in positive (A) and
negative (B) ion mode. Asterisks indicate PC(36:4) (m/z 782.569; [MþHþ]) and arachidonic acid (FFA(20:4),m/z 303.234; [M-H]). C and D, LESA-MS spectra
at three sites across lung tumors ("MYC activated," n ¼ 4; "MYC inactive," n ¼ 6; "KRAS only," n ¼ 4) were used to construct an OPLS-DA model (C)
and related loadings (D) plot. A signiﬁcant decrease over time was observed for arachidonic acid [FFA(20:4)] and related lipids following deactivation of MYC.
E, MYC deactivation was achieved by the removal of tamoxifen from the diet; as an additional control, "KRAS-only" lung tumors from mice on a
normal diet and a tamoxifen-containing diet were compared, with no signiﬁcant (n.s) differences in lipid content noted. F, higher levels of
eicosanoids, including HETEs, prostaglandins, and thromboxanes were measured by LC-MS/MS in "MYC-activated" compared with "MYC-inactive"
samples. Data are mean  SEM ( , P < 0.05;  , P < 0.01;  , P < 0.001).
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normal and tumor tissue, and monitoring changes following the
deactivation ofMYC. Themost intriguing discovery was a striking
increase in arachidonic acid and arachidonate-containing phos-
pholipids in "MYC activated" tumors compared with normal
tissue. These levels dramatically decreased with time in tumors
following MYC deactivation. Arachidonic acid is an omega-6
polyunsaturated fatty acid, and is liberated from membrane
phospholipids by cPLA2 (28). The metabolism of arachidonic
acid by COX, LOX, and cytochrome P450 generates eicosanoids,
including prostaglandins, leukotrienes, and HETEs (Fig. 6F).
Although the functional role of many eicosanoids remains
unknown, a number act as potent mediators of inﬂammation,
andhave recently been implicated in cancers through effecting cell
proliferation, survival, angiogenesis, migration, and invasion
(36–38). In particular, arachidonic acid and its eicosanoid meta-
bolites have been shown to activate peroxisome proliferator-
activated receptors (PPAR), induce nuclear translocation of NF-
kb and to activate the PI3K signaling cascade (PI3K/AKT), amajor
driver for proliferation in cancer (33, 39).
In this study, we uncovered an increase in arachidonic acid–
derived eicosanoids in cancerous lung tissue from "MYC acti-
vated" mice, notably metabolites of the COX and LOX path-
ways (Fig. 6F). We further found increased cPLA2 activity,
which decreased with time following MYC deactivation, con-
comitant with decreased downstream metabolite levels. High
cPLA2 staining was found in mitotic cells, suggesting a role
for cPLA2 or its metabolites in proliferation. cPLA2 is activated
by phosphorylation via the MAPK pathway, and effectors may
include TNFa and IL1b, among many others (33, 40). Here,
we found that gene expression for IL1b in particular was linked
Figure 5.
Cytosolic phospholipase A2 activity linked to MYC. A, immunostaining of lung tumors for the active phosphorylated cPLA2 revealed a decrease in
positively stained cells with MYC deactivation. B, quantiﬁcation of staining revealed a signiﬁcant decrease in phosphorylated cPLA2 levels with
time after MYC deactivation. C, cPLA2 activity was determined using an enzyme assay and found to decrease with MYC deactivation. D, closer inspection of
staining for phosphorylated (left) or total (right) cPLA2 revealed that many of the positively stained cells were visibly undergoing mitosis (black arrows).
E, transcript quantiﬁcation in lung revealed that only Cox2 and Alox5 mRNAs were increased in "MYC activated" compared with "KRAS-only" lung
tissue. These levels decreased following MYC deactivation. F, similarly, Tnf-a and Il-1b mRNAs increased with MYC activation. Data are mean  SEM
( , P < 0.05;  , P < 0.01).
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to MYC activity. We additionally uncovered a link between
upregulated COX-2 and 5-LOX gene expression and MYC
activity. Interestingly, both genes contain an E-box sequence
in their promoter region, so could be directly regulated by MYC
abundance (41, 42). Alternatively, their response to MYC may
be a result of complex interdependencies, occurring down-
stream of primary MYC targets. Inhibiting these two pathways
in vivo resulted in marked reduction in tumor load and signif-
icantly decreased proliferation, highlighting their potential as
targets for lung adenocarcinoma treatment, particularly with
the involvement of MYC (43, 44).
Upregulation of lipid synthesis is a hallmark of cancers as a
strategy to generate new cell membranes and signalingmolecules,
thus enabling the extensive proliferation of tumor cells (45).
When comparing tumor and normal lung tissue, we observed a
relative increase in PIs in tumors. PIs are precursors of the PI
polyphosphates (PIPn), an important class of signalingmolecules
involved in the PI3K signaling cascade. PIs are not considered to
be rate-limiting for the formation of PIPn, and their roles inmany
cancers are yet to be deﬁned. However, speciﬁc PIs have been
proposed as biomarkers for prostate cancer (46), and have been
shown to be elevated in human lung tumors (47). One possibility
here is that PI may provide an alternative source of arachidonic
acid, because the most abundant PI identiﬁed was arachidonate-
containing PI(38:4).
Although lipids serve as signaling precursors and structural
components of the cell membrane, they also make up approx-
imately 90% of pulmonary surfactant, which lines the alveolar
surface of healthy lung. This ﬂuid is responsible for reducing
surface tension at the air-water interface, allowing efﬁcient
exchange of gases (48, 49). The lipid content of this surfactant
is predominantly PC and PG, the most abundant of which are
PC(32:0) (50 %) and PC(32:1) (10 %; refs. 27, 49). During
our analysis, we found that PC(32:0), PC(32:1) and PGs were
substantially increased in normal mouse lung tissue compared
with tumor tissue. This may be as a result of the breakdown of
the ﬁne alveolar structure with tumor progression. An alternate
explanation is the composition of surfactant in lung tumors
Figure 6.
In vivo inhibition of COX/5-LOX pathways. A and B, licofelone treatment in mice with KRAS-driven adenocarcinoma and high MYC resulted in reduced tumor
load (H&E; magniﬁcation, 40; A) and proliferation staining (Ki67; x200; B) compared with vehicle. C and D, quantiﬁcation of proliferation (C) and apoptosis
(D) by Ki67 and cleaved caspase-3 (cc3) immunostaining, respectively, was performed. E, LC-MS/MS conﬁrmed reduction of 5-LOX and COX-2
metabolites. Data are mean  SEM (n ¼ 4);  , P < 0.01 (Mann–Whitney U test). F, cPLA2 is activated by phosphorylation through the MAPK
pathway. Phosphorylated cPLA2 liberates arachidonic acid from intact phospholipids, which is metabolized by the COX, LOX, and cytochrome P450
pathways to form eicosanoids. Complex feedback mechanisms exist between LOX/COX, cPLA2 pathways, and proinﬂammatory cytokines such as
TNFa and IL1b. Eicosanoids have a wide range of effects that can result in increased proliferation, cell survival and angiogenesis. Red arrows
indicate a positive correlation to MYC activity level, as determined in this study.
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may be altered by catabolic phospholipase activity or acyl chain
elongation (50).
Finally, differences were observed for the distribution of salt
adducts, with a higher proportion of sodiated phospholipids
present in normal tissue, and potassiated lipids in tumor
regions. In healthy cells, there is typically higher intracellular
Kþwhereas extracellular ﬂuid such as lung surfactant contains a
higher proportion of Naþ. This balance can be disrupted by the
upregulation of Naþ/Hþ exchangers in cancerous cells with
high aerobic glycolytic activity. Furthermore, dysregulation of
potassium channels, Naþ/Kþ ATPase or Naþ/Ca2þ exchangers
may also be important, particularly given the role of Ca2þ in
cPLA2 activation (51, 52). All these could result in altered Naþ
permeability into the cell and/or export of Kþ. An increased
extracellular Kþ associated with tumors may account for the
preference of Kþ adduct formation during ionization of phos-
pholipids by MALDI-MSI, and offers unique insights into the
tumor microenvironment.
Conclusion
Using a transgenic mouse model of KRAS-driven lung ade-
nocarcinoma with reversible activation of MYC, we compared
the lipid proﬁles of normal and tumor tissue, ﬁnding increased
signaling-precursor lipids and eicosanoids, and decreased sur-
factant lipids in tumors. When MYC was deactivated, the tumor
lipid signature markedly changed, with a large relative decrease
in arachidonic acid and related lipids. This coincided with
decreased cPLA2 activity and downstream metabolites, and
decreased transcript levels for COX-2 and 5-LOX in lung tissue.
We hypothesize that tumors with high MYC activity have
increased levels of arachidonic acid as a consequence of
increased cPLA2 activity. Free arachidonic acid serves as a
substrate pool for upregulated eicosanoid synthesis, which can
inﬂuence cancer progression in multiple ways. Dual inhibition
of COX/5-LOX pathways in vivo resulted in reduced prolifera-
tion and a marked decrease in tumor load, and suggests these
druggable pathways warrant further investigation as lung
cancer therapies. MS imaging and associated surface analysis
techniques have been shown here as powerful analytic tools,
capable of obtaining detailed and spatially precise molecular
signatures of tumor sub-environments, and paving the way for
further studies in the exciting and rapidly developing ﬁeld of
lipidomics.
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